Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2010, Vol. 15 ›› Issue (8): 861-865.

Previous Articles     Next Articles

Effects of monoclonal antibodies against human stathmin combined paclitaxel on proliferation of human breast carcinoma cell line MCF-7

YUAN Shao-fei1, CHEN Wen-jun1, ZHENG Wei-e1, DU Hong-yan1, LI Ming2, ZHANG Wu1, CHEN Hua1, WU Li-li1   

  1. 1Cancer Center, the Third Affiliated Hospital,Wenzhou Medical College, Wenzhou 325000, Zhejiang,China;
    2School of Biological Technology, Southern Medical University, Guangzhou 510515, Guangdong, China
  • Received:2010-03-11 Revised:2010-04-24 Online:2010-08-26 Published:2020-09-17

Abstract: AIM: To investigate the effects of monoclonal antibodies against stathmin combined paclitaxel on the proliferation of MCF-7 cells.METHODS: MCF-7 cells were treated with monoclonal antibodies against stathmin, paclitaxel alone or their combination, with theuntreated cells used as the control, 24,48,72,96 hours later, the cell growth condition was observed by invert microscope and inhabitation rate was studied by MTT assay ; The apoptosis was analyzed by flow cytometry with Annexin V/PI.RESULTS: The population decreased and shape, size changed after treating with different concentration of experimental groups. Monoclonal antibodies against stathmin and paclitaxel used alone or in combination both inhibited the proliferation of MCF-7 cells,the inhibition ratio of their combination was more higher(P<0.05), and a synergistic effect of the two agents was noted in their combined action (P<0.05). Combined treatment of the cells resulted in significantly higher apoptosis rate than that in the other groups (P<0.05).CONCLUSION: Monoclonal antibodies against stathmin and paclitaxel used alone or in combination both can inhibit proliferation of MCF-7 cells and induce apoptsis. A synergistic effect is observed between the monoclonal antibodies against stathmin and paclitaxel in their inhibition of MCF-7 cell proliferation.

Key words: Monoclonal antibodies against stathmin, Paclitaxel, Breast carcinoma, Proliferation, Apoptosis

CLC Number: